Over 50 pharmaceutical companies are actively developing 55+ pipeline therapies for chronic hepatitis B virus (HBV) infection, signaling a robust research landscape aimed at achieving functional cures beyond current suppressive treatments.
The FDA has granted fast-track designation to GSK's bepirovirsen, an antisense drug, for chronic hepatitis B (CHB) treatment, expediting its review process.
A Phase II trial of xalnesiran plus immunomodulators showed significant hepatitis B surface antigen (HBsAg) loss in patients with chronic HBV infection.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.